| Title | TRX-4 (TolerRx Inc). | | Author(s) | Brown WM | | Institution | Paddock Laboratories Inc, 3940 Quebec Avenue North, Minneapolis, MN 55427, USA. wbrown@paddocklabs.com | | Source | IDrugs 2006 Apr; 9(4):283-91. | | MeSH | Antibodies, Monoclonal
Antigens, CD3
Clinical Trials, Phase I
Clinical Trials, Phase II
Diabetes Mellitus, Type 1
Graft Rejection
Humans
Kidney Transplantation
Patents
Psoriasis
Treatment Outcome
| | Abstract | TolerRx Inc, under license from BTG plc, is developing TRX-4, an anti-CD3 humanized monoclonal antibody for the potential treatment of type 1 diabetes and psoriasis. Phase II trials of the therapeutic antibody in type 1 diabetes have been completed and the company is planning a pivotal phase III trial for this indication. TolerRx is also enrolling psoriasis patients in a phase Ib clinical study of TRX-4. TRX-4 has been awarded Orphan Drug status for recent-onset type 1 diabetes. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 16596483 |
|
